



September 26, 2007

Honourable Brad Cathers  
Yukon Legislative Assembly  
Box 2703  
Whitehorse, Yukon  
Y1A 2C6

**Sent via email to:**  
**brad.cathers@gov.yk.ca**  
**Original mailed**

Dear Minister Cathers:

In an effort to work collaboratively with government, Arthritis Consumer Experts and the Canadian Arthritis Patient Alliance are writing to bring your attention to the June 20, 2007 Common Drug Review's **Canadian Expert Drug Advisory Committee (CEDAC) recommendation that adalimumab (Humira®) be added to provincial drug benefit plans for people with active ankylosing spondylitis, who have had an inadequate response to at least three different nonsteroidal anti-inflammatory drugs (NSAIDS) and, in patients with peripheral joint involvement who have failed to respond to methotrexate or sulfasalazine (See attached CEDAC recommendation.)**

Currently, people living with ankylosing spondylitis in the Yukon have no biologic medications available to them on the provincial drug reimbursement formulary. Adalimumab (Humira®) has been under review since approximately November 2006 and infliximab (Remicade®) has been under review since 2005 yet neither have been approved. The situation is the same for the other two biologic response modifiers on the market that have all been under review for significant periods of time. This continues to be unacceptable to the arthritis community and should be to the Government of the Yukon, too.

Given this strong CEDAC recommendation and your Ministry's support for the Common Drug Review process, we urge you, as Minister of Health, **to take the immediate necessary steps to have adalimumab listed on the provincial drug benefit plan for people with ankylosing spondylitis.** We remind you that this therapy is intended to treat people with ankylosing spondylitis. Providing a timely reimbursement listing for this medication will ensure that people in the Yukon living with ankylosing spondylitis are able to reduce the pain and disability associated with delaying treatment and improve their quality of life.

We thank you in advance for considering our request, and await word from you on your listing decision for adalimumab for ankylosing spondylitis.

Sincerely,



Cheryl Koehn  
President  
Arthritis Consumer Experts  
Person with rheumatoid arthritis



Ron Woznow, PhD  
Executive Director  
The Arthritis Society,  
BC and Yukon Division



Anne Dooley  
President, Canadian Arthritis Patient Alliance  
Person with rheumatoid arthritis

C.c. Dianne Tait, Manager, Extended Benefits and Pharmaceutical Programs

**Note: Please address reply correspondence to Ms. Cheryl Koehn, Arthritis Consumer Experts, 910 B Richards Street, Vancouver, BC V6B 3C1; or, Anne Dooley, 206 Garrison Crescent, Saskatoon, SK. S7H 2Z8**